GSEP
RYTM icon

Golden State Equity Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Golden State Equity Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37
Closed -$3.22K – 1469
2026
Q1 		$3.22K Buy
+37
New +$3.6K ﹤0.01% 1572

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Golden State Equity Partners's RYTM Position: Q2 2026 in Review

Golden State Equity Partners sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 37 shares — an estimated $3.22K sold.

Golden State Equity Partners first reported a position in RYTM in Q1 2026 and held it in 1 quarter. The position peaked at $3.22K in Q1 2026. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Golden State Equity Partners reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 37 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $3.22K.
  • Golden State Equity Partners first reported a position in Rhythm Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Rhythm Pharmaceuticals position peaked at $3.22K in Q1 2026.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.